Chantal Pharmaceutical to report profitable FY 1995.LOS ANGELES--(BUSINESS WIRE)--Sept. 27, 1995--Chantal Pharmaceutical Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CHTL) said today that for the first year in the company's history, it will report earnings. For the fiscal year ended June 30, 1995, earnings are estimated to be in excess of $.02 per share on revenue of $7,214,938, the exact figures being subject to final audit judgments. The announcement was made by Chantal Burnison, chairman and chief executive officer of Chantal Pharmaceutical Corp., who noted that the successful results are attributable to the sales of Chantal Ethocyn Skin Care Line of products, which the company began marketing in Aug. 1994. Burnison noted that fourth quarter 1995 revenue was strong at $3,358,889 and earnings are estimated to be in excess of $.09 for the quarter. The company also announced that it is filing with the SEC for an extension for the filing of the company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and that it expects to file such report within the permitted extended period. The company also announced that it has executed a Letter of Intent with an organic chemical production laboratory in Switzerland for the scale up production of the company's proprietary Ethocyn skin care ingredient. The terms and conditions set forth in the Letter of Intent are more favorable to the company, with respect to both expediency and cost, than those which were previously available. Burnison in making the announcement commented that "The company is pleased to have a laboratory which has been utilized by numerous major pharmaceutical and chemical companies to complement the company's existing manufacturing capacity at its Kaiserslautern, Germany laboratory." Chantal Pharmaceutical Corp. has executive offices, telemarketing and warehouse facilities in Los Angeles, with a laboratory in Kaiserslautern, Germany. In addition to marketing Chantal Ethocyn Skin Care line, the company is engaged in the research and development of topical and systemic pharmaceutical and therapeutic compounds for the treatment of androgen androgen (ăn`drəjən): see testosterone. androgen Any of a group of hormones that mainly influence the development of the male reproductive system. mediated disorders such as acne, hirsutism Hirsutism Definition Excessive growth of facial or body hair in women is called hirsutism. Description Hirsutism is not a disease. The condition usually develops during puberty and becomes more pronounced as the years go by. , male pattern baldness male pattern baldness n. A progressive, diffuse loss of scalp hair in men that begins in the twenties or early thirties, depends on the presence of the androgenic hormone testosterone, and is caused by a combination of genetic and hormonal factors. , benign prostate hypertrophy hypertrophy (hīpûr`trəfē), enlargement of a tissue or organ of the body resulting from an increase in the size of its cells. Such growth accompanies an increase in the functioning of the tissue. and the treatment of certain cancers. CONTACT: Martin E. Janis Public Relations public relations, activities and policies used to create public interest in a person, idea, product, institution, or business establishment. By its nature, public relations is devoted to serving particular interests by presenting them to the public in the most , Chicago Bev Jedynak, 312/943-1100 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion